

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



友芝友生物製藥

**WUHAN YZY BIOPHARMA CO., LTD.**

**武漢友芝友生物製藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 2496)**

**INSIDE INFORMATION  
PROFIT ALERT — EXPECTED REDUCTION IN LOSS**

This announcement is made by Wuhan YZY Biopharma Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to the Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company wishes to inform the shareholders and potential investors of the Company that based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2024 (the “**Reporting Period**”) and information currently available, it is expected that the Group will record a decrease in consolidated loss for the Reporting Period of no less than 35%, compared to the consolidated loss of RMB191.7 million for year ended December 31, 2023.

The Board believes that the aforementioned reduction in consolidated loss is primarily attributable to (i) the transaction under the license and collaboration agreement (the “**License and Collaboration Agreement**”) entered into between the Company and Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (正大天晴藥業集團股份有限公司) on October 7, 2024 (for details of the License and Collaboration Agreement, please refer to the Company’s announcement dated October 7, 2024); and (ii) listing expenses of approximately RMB24.6 million was recorded in 2023 (2024: nil).

The Company is still in the process of finalising the annual results for the year ended December 31, 2024. The Board wishes to emphasize that the information contained in this announcement is only a preliminary assessment by the management of the Company based on the figures and information currently available. The information contained in this announcement has not been audited or reviewed by the Company’s auditor and is subject to adjustments and changes.

Details of the Group’s financial results and performance for the Reporting Period will be disclosed in the Company’s annual results announcement, which is expected to be published at the end of March 2025.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Wuhan YZY Biopharma Co., Ltd.**  
**Dr. Zhou Pengfei**

*Chairman of the Board, Executive Director and Chief Executive Officer*

Wuhan, PRC, March 24, 2025

*As of the date of this announcement, the Board comprises Dr. Zhou Pengfei as executive Director, Dr. Yuan Qian, Dr. Zhou Hongfeng, Mr. Pang Zhenhai, Dr. Hui Xiwu, Ms. Liang Qian, Mr. Wen Zhicheng and Mr. Xie Shouwu as non-executive Directors, and Dr. Cheng Bin, Ms. Fu Lili, Dr. Deng Yuezhen and Dr. Chen Bin as independent non-executive Directors.*